

Premarket Approval (PMA) Submissions Workshop

AdvaMed Office
1301 Pennsylvania Ave. N.W. Suite 400 Washington, D.C.
February 6 – 7, 2025

Feb 6, 2025

- 8:30 – 9:00 am** **Registration Check-In and Continental Breakfast**
- 9:00 – 9:05 am** **Welcome and Introductions**
- 9:05 – 10:00 am** **Beginning at the Beginning**
Elaine Tseng, Partner, King & Spalding
- When is a De Novo or PMA required
 - PMA: what to expect
 - What are the standards of evidence
 - What are the standards of review
 - Will submission go to panel
 - How much will it cost
 - How long will it take to get approval
- 10:00 – 10:45 am** **Development of a PMA Submission Strategy**
Tony Blank, Senior Director of Regulatory Affairs, AtriCure
- Product definition
 - Development of testing requirements and strategy
 - Desired patient population
 - Desired claims
 - Early interactions with FDA
 - Planning for product iterations
- 10:45 – 11:00 am** **Break**
- 11:00 – 12:00 pm** **Mechanics of PMA Quality System Submission Development and Review**
Jennifer Bolton, Senior Fellow, Regulatory Affairs, Boston Scientific
- Defining data requirements
 - Required elements
 - Presentation of information with clarity
 - Expectations during review
 - Best practices
 - Manufacturing & Quality Systems
 - Case for Quality
- 12:00 – 1:00 pm** **Networking Lunch**

Important Notice

The information provided in this course represents the personal opinions of the instructors and does not necessarily represent the opinions of AdvaMed staff. Companies relying on the information do so at their own risk and assume the risk of any subsequent liability that results from relying on the information. The information does not constitute legal advice.



AdvaMed

Advanced Medical Technology Association
Events & Education

1:00 – 2:00 pm

During Submission Review

Jennifer Bolton, Senior Fellow, Regulatory Affairs, Boston Scientific

- Interactions with the FDA
- When/How to expect questions
- Types of letters
- Timelines
- Day 100 meetings
- Labeling review

2:00 – 3:00 pm

Conditions of Approval Studies

Jennifer Bolton, Senior Fellow, Regulatory Affairs, Boston Scientific

- Criteria and objectives
- Early collaboration with FDA
- Reaching agreement
- Reporting outcomes
- 522 Studies

3:00 – 3:15 pm

Break

3:15 – 4:15 pm

Preparation for Advisory Panels

Jessica Ringel, Partner, King & Spalding

- When?
- Who are the panel members?
- Why have a panel meeting?
- Preparation for a panel meeting
- What to expect before, during, and after
- Best practices

4:15 – 5:15 pm

Networking Reception

Important Notice

The information provided in this course represents the personal opinions of the instructors and does not necessarily represent the opinions of AdvaMed staff. Companies relying on the information do so at their own risk and assume the risk of any subsequent liability that results from relying on the information. The information does not constitute legal advice.

Feb. 7, 2025

- 8:30 – 9:00 am** **Continental Breakfast**
- 9:00 – 10:00 am** **Inspection Activity**
Monica Montanez, Principal Strategy Consultant, NAMSA
- Pre-approval inspections
 - How to prepare for an inspection
- 10:00 – 11:00 am** **Dealing with the Unexpected**
Tony Blank, Senior Director of Regulatory Affairs, AtriCure
- Clinical outcomes
 - Animal test results
 - Adverse panel recommendation
- 11:00 – 11:15 am** **Break**
- 11:15 am – 12:30 pm** **The Care and Feeding of Approved PMAs**
Monica Montanez, Principal Strategy Consultant, NAMSA
- Periodic (“Annual”) Reports
 - Supplemental Submissions
 - 30-day notices
- 12:30 – 1:30 pm** **Networking Lunch**
- 1:30 – 3:30 pm** **Applied Learning and Breakout Discussions**
Tony Blank, Senior Director of Regulatory Affairs, AtriCure
**In person participants, only*
- PMA Recap
 - Facilitated Breakout Group Deep Dive
 - Hypothetical Case Studies
 - Key Takeaways
 - Regroup for Final Program Q&A
- 3:30 pm** **Adjournment**

Important Notice

The information provided in this course represents the personal opinions of the instructors and does not necessarily represent the opinions of AdvaMed staff. Companies relying on the information do so at their own risk and assume the risk of any subsequent liability that results from relying on the information. The information does not constitute legal advice.